Novartis’s Q3 2016 net income $10,9B shorter than last year

Novartis has reported net income of $5.8 billion compared to $16.7 billion in the prior-year period.

Basic earnings per share decreased to $2.42 from $6.94.

The prior-year period benefitted from the net income from discontinued operations, which included $12.8 billion of exceptional pre-tax divestment gains from the portfolio transformation transactions and $0.5 billion of additional pre-tax transaction related expenses, said Novartis in its press release issued Tuesday.

Commenting on the results, Joseph Jimenez, CEO of Novartis, said:

“Novartis delivered a solid Q3 despite the Gleevec generic impact in the US, due to the strong performance of our Growth Products. We continued to drive innovation, with positive pipeline readouts for LEE011 in advanced breast cancer, BAF312 in SPMS and AMG 334 in episodic migraine. We are continuing to invest for the future, as we manage the Gleevec loss of exclusivity in 2016 and 2017.”

Leave a Reply

Please log in using one of these methods to post your comment:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s